Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: a test-negative case-control study

References

• Department of Medical Sciences, Ministry of Public Health of Thailand. SARS-CoV-2 variants in Thailand, 1 November 2021. Available from: https://www3.dmsc.moph.go.th/.
   Google Scholar
• Jara A, Undurraga EA, González C, et al. Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile. N Engl J Med. 2021;385:875–884.
   PubMed Web of Science ®Google Scholar
• Ranzani OT, Hitchings MDT, Dorion M, et al. Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of COVID-19 in Brazil: test negative case-control study. Br Med J. 2021;374:n2015. doi:10.1136/bmj.n2015.
   PubMed Web of Science ®Google Scholar
• Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111.
   PubMed Web of Science ®Google Scholar
• de Gier B, Andeweg S, Joosten R, et al. Vaccine effectiveness against SARS-CoV-2 transmission and infections among household and other close contacts of confirmed cases, the Netherlands, February to May 2021. Euro Surveill. 2021;26(44). doi:10.2807/1560-7917.ES.2021.26.44.2100977.
   Google Scholar
• Sadoff J, Gray G, Vandebosch A, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. 2021;384:2187–2201.
   PubMed Web of Science ®Google Scholar
• Thomas SJ, Moreira ED Jr, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. N Engl J Med. 2021;385:1761–1773.
   PubMed Web of Science ®Google Scholar
• El Sahly HM, Baden LR, Essink B, et al. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. N Engl J Med. 2021;385:1774–1785.
   PubMed Web of Science ®Google Scholar
• Tang P, Hasan MR, Chemaitelly H, et al. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 delta variant in Qatar. Nat Med. 2021 Nov 2. doi:10.1038/s41591-021-01583-4. Online ahead of print.
   Web of Science ®Google Scholar
• Seppälä E, Veneti L, Starrfelt J, et al. Vaccine effectiveness against infection with the delta (B.1.617.2) variant, Norway, April to August 2021. Euro Surveill. 2021;26(35):2100793. doi:10.2807/1560-7917.ES.2021.26.35.2100793.
   PubMedGoogle Scholar
• Fowlkes A, Gaglani M, Groover K, et al. Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection among frontline workers before and during B.1.617.2 (delta) variant predominance – eight U.S. locations, December 2020-August 2021. MMWR Morb Mortal Wkly Rep. 2021;70:1167–1169.
   PubMed Web of Science ®Google Scholar
• Nanduri S, Pilishvili T, Derado G, et al. Effectiveness of Pfizer-BioNTech and Moderna vaccines in preventing SARS-CoV-2 infection among nursing home residents before and during widespread circulation of the SARS-CoV-2 B.1.617.2 (delta) variant – national healthcare safety network, March 1–August 1, 2021. MMWR Morb Mortal Wkly Rep. 2021;70:1163–1166.
   PubMed Web of Science ®Google Scholar
• Tartof SY, Slezak JM, Fischer H, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. 2021;398:1407–1416.
   PubMed Web of Science ®Google Scholar
• Barda N, Dagan N, Cohen C, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet. 2021 Oct 29. doi:10.1016/S0140-6736(21)02249-2. Online ahead of print.
   PubMed Web of Science ®Google Scholar
• Wang F, An Z, Rodewald L, et al. Guangdong's study of the effectiveness of China's inactivated vaccines against the SARS-CoV-2 B.1.617.2 (delta) variant. China CDC Wkly. 2021;3:728–730.
   PubMedGoogle Scholar
• Li XN, Huang Y, Wang W, et al. Effectiveness of inactivated SARS-CoV-2 vaccines against the delta variant infection in Guangzhou: a test-negative case-control real-world study. Emerg Microbes Infect. 2021;10:1751–1759.
   PubMed Web of Science ®Google Scholar
• Jantarabenjakul W, Chantasrisawad N, Puthanakit T, et al. Short-term immune response after inactivated SARS-CoV-2 (CoronaVac®, Sinovac) and ChAdOx1 nCoV-19 (Vaxzevria®, Oxford-AstraZeneca) vaccinations in health care workers. Asian Pac J Allergy Immunol. 2021. doi:10.12932/AP-250721-1197. Online ahead of print.
   Web of Science ®Google Scholar
• Niyomnaitham S, Sewatanon J, Senawong S, et al. Safety and immunological response following heterologous primary series of COVID-19 vaccination: the preliminary report focusing on the delta variant. Available from: https://sicres.org/wp-content/uploads/2021/08/Poster-hetero-in-Eng_8pm.pdf.
   Google Scholar
• Patel MK, Bergeri I, Bresee JS, et al. Evaluation of post-introduction COVID-19 vaccine effectiveness: summary of interim guidance of the World Health Organization. Vaccine. 2021;39:4013–4024.
   PubMed Web of Science ®Google Scholar
• Department of Medical Services, Ministry of Public Health of Thailand. Guidelines on diagnosis, treatment and prevention of Covid-19 in hospitals, the revised version, May 6th, 2021. Available from: https://covid19.dms.go.th/.
   Google Scholar
• Wang Y, Chen R, Hu F, et al. Transmission, viral kinetics and clinical characteristics of the emergent SARS-CoV-2 delta VOC in Guangzhou. China EClinicalMedicine. 2021 Oct;40:101129. doi:10.1016/j.eclinm.2021.101129. Online ahead of print.
   PubMedGoogle Scholar
• World Health Organization. COVID-19 clinical management: living guidance, 25 January 2021. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1.
   Google Scholar
• Bernal JL, Andrews N, Gower C, et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (delta) variant. N Engl J Med. 2021;385:585–594.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Evaluation of COVID-19 vaccine effectiveness. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccine_effectiveness-measurement-2021.1.
   Google Scholar
• Goldberg Y, Mandel M, Bar-On YM, et al. Waning immunity after the BNT162b2 vaccine in Israel. N Engl J Med. 2021 Oct 27. doi:10.1056/NEJMoa2114228. Online ahead of print.
   Google Scholar
• Chemaitelly H, Tang P, Hasan MR, et al. Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar. N Engl J Med. 2021 Oct 6. doi:10.1056/NEJMoa2114114. Online ahead of print.
   Google Scholar
• Levine-Tiefenbrun M, Yelin I, Alapi H, et al. Viral loads of delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2. Nat Med. 2021 Nov 2. doi:10.1038/s41591-021-01575-4. Online ahead of print.
   Web of Science ®Google Scholar
• Borobia AM, Carcas AJ, Pérez-Olmeda M, et al. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet. 2021;398:121–130.
   PubMed Web of Science ®Google Scholar
• Schmidt T, Klemis V, Schub D, et al. Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination. Nat Med. 2021;27:1530–1535.
   PubMed Web of Science ®Google Scholar
• Liu X, Shaw RH, Stuart ASV, et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet. 2021;398:856–869.
   PubMed Web of Science ®Google Scholar